Posted by Michael Wonder on 04 Nov 2021
UK approval for MSD/Ridgeback’s COVID-19 anti-viral medicine
4 November 2021 - The UK MHRA has authorised MSD and Ridgeback Therapeutics’ COVID-19 anti-viral medicine molnupiravir.
The UK approval is the first authorisation for molnupiravir in the world, with additional application currently under review including with the US FDA and the EMA.
